Back to Top

Publisher Policies

Forensic Genomics is a single-blinded peer reviewed journal. All submissions are subject to peer review. Upon submission, manuscripts are assessed by the Editor, Associate Editor, or member of the editorial board for suitability for Forensic Genomics.  For those that are deemed appropriate, a minimum of two expert reviewers in the area of study will be selected to assess the scientific basis and significance of the manuscript. Following peer review, the Editor and/or Associate Editors will determine if the paper requires further revision, is accepted in its current form, or is unacceptable for publication.

Confidentiality in Peer Review
Editors and reviewers must maintain strict confidentiality of manuscripts during the peer review process.  Sharing a manuscript in whole or in part is impermissible prior to its official publication date.  Reviewers are expected to retain their anonymity and are prohibited from contacting authors directly.  All content of any submission is considered private and confidential and should not be shared with anyone without the express written approval of the Editor(s)-in-Chief of Forensic Genomics.

Sharing of Materials during Peer Review
Authors must honor any reasonable request for materials, methods, or data necessary to reproduce or validate the research findings during peer review unless it violates the privacy or confidentiality of human research subjects.

Peer Review of Papers Authored by the Editor(s)-in-Chief and/or Associate Editor(s)
The Editor(s)-in-Chief and Associate Editor(s) will recuse themselves from participating in the review process of any manuscript in which they are listed as an author and/or if there is a potential or actual competing interest.  The peer review process on these submissions will be handled by another senior member of the editorial board.

Self-Citation and Self-Plagiarism
Forensic Genomics is committed to maintaining the integrity of the peer review process by upholding the highest standards for all published articles.  Plagiarized manuscripts will be rejected immediately. While a manuscript submission may contain some redundancy in language and content (i.e., Materials and Methods) compared to work previously published by authors, self-plagiarism can infringe upon copyright. To avoid plagiarism, be sure to properly cite and reference all published works.  (Deposition of a preprint on a preprint server is not considered as prior publication and will not impact consideration of any submitted manuscript.)

Time in Review
The journal strives to maintain a short, but thorough peer review process. The average time in review is 21 days but the Editor will strive to expedite manuscript handling if circumstances dictate.

ATTENTION:
To ensure the receipt of all communications from the journal editorial office and publisher, please whitelist the following domains to prevent spam filter detection or non-deliverables:

•    manuscriptcentral.com
•    amazonses.com
•    liebertpub.com

Failure to whitelist these domains may significantly hinder the progress of peer review on submitted manuscripts, and the production process of accepted papers.

AUTHORSHIP
Definition of Authorship
Authorship, as defined by the International Committee of Medical Journal Editors, is based on the following criteria:

•    Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; AND
•    Drafting the work or revising it critically for important intellectual content; AND
•    Final approval of the version to be published; AND
•    Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Non-Author Contributors
Contributors who meet fewer than all four of the above criteria for authorship should not be listed as authors, but they should be acknowledged in the Acknowledgments section with a description of their contribution to the work.
For further information, visit the International Committee of Medical Journal Editors’ website.

ORCID IDs
Submitting authors are required to complete their submissions using an ORCID identifier. Please visit the ORCID website for more information, or to register.

AUTHORSHIP LIMIT
There is a limit of 35 of authors permitted on a single submission, but in cases where there are 20 or more co-authors, Forensic Genomics recommends that a collective working group, team, or consortium name be provided and the individual authors and their affiliations listed in the Acknowledgements section.  This will ensure the proper listing of all authors in the indexing services in which Forensic Genomics is included.

CORRESPONDING AUTHOR**
One author should be designated on the manuscript title pages as the corresponding author who will be responsible for communication between the authors and the journal editorial office(s) and publisher.  This individual will be responsible for ensuring all authors submit copyright forms as well as receiving and responding to page proofs, and managing any other necessary contact during the peer review and/or production processes.
**NOTE: Due to configuration restraints, the submission system permits only one author to be identified as the corresponding author of record.  However, we recognize that some submissions call for more than one corresponding author to be noted.  In such cases, select one author to be the main point of contact and/or corresponding author for all communications regarding the peer review process of the paper, but on the title page of the manuscript, designate additional co-corresponding authors by including an asterisk after the authors' names in the byline, and include an accompanying footnote on the title page that reads, "Co-corresponding authors." 

Please ensure that the title page of the submission page carries the full affiliation details and email addresses of all authors who should be noted as a corresponding author. If the paper is accepted for publication, the full contact information for all designated co-authors will be listed at the end of the article as per usual journal style.

WORKING GROUPS / TEAMS/ CONSORTIUMS AUTHORSHIP
Working Groups, teams, or consortiums may be listed as an “author” in the manuscript byline, but the complete listing of members’ names and affiliations should be included in the Acknowledgment section of the manuscript. Do not list the names in a footnote on the title page.

VARIATIONS OF AUTHORSHIP
It is permissible to list up to three authors as co-first authors, or as contributing equally to the work. Include an asterisk (*) next to the authors' names who are considered as first authors, and a corresponding footnote, using the asterisk, on the title page that reads, "These authors contributed equally to this work and are considered to be co-first authors."

CHANGES IN AUTHORSHIP  
Authorship should be determined prior to submission.  Submitting agents should use extreme care to ensure the accuracy of the author list and their correct affiliations.  Changes in authorship after submission or acceptance of a paper are generally not permitted, but the editorial leadership recognizes that it may be required in certain extraordinary and rare circumstances. The policy of Forensic Genomics for such cases is as follows:

•    Authorship may be altered after submission or acceptance of a paper ONLY with the express written approval of all authors named on the manuscript, as well as the individual(s) being added and/or deleted. The Publisher will provide a specialized form that all authors will be required to sign and return.
•    A request to alter authorship must be made in writing from the corresponding author to the Editor-in-Chief, with a detailed explanation for the request, and the names and affiliations of the authors requiring addition and/or deletion.
•    Upon receipt of the request and all written approvals of all involved parties, the Editor-in-Chief will consider the request, render a decision, and notify the corresponding author.
•    Authorship will not be altered without the completed and signed forms from each author.
•    Alterations of authorship post-publication is not permitted.
•    Post-publication changes or alterations to authorship of published conference abstracts are not permitted.

ATTENTION:
To ensure the receipt of all communications from the journal editorial office and publisher, please whitelist the following domains to prevent spam filter detection or non-deliverables:

•    manuscriptcentral.com
•    amazonses.com
•    liebertpub.com

Failure to whitelist these domains may significantly hinder the progress of peer review on submitted manuscripts, and the production process of accepted papers.

EXCLUSIVITY  
Manuscripts should be submitted with the understanding that they have neither been published, nor are under consideration for publication elsewhere, in the same form or substantially similar form, except in the form of a conference/meeting abstract.  If work was presented at a conference, supply the name, date, and location of the meeting as a footnote on the title page of the submission.

USE OF ENGLISH LANGUAGE  
All submissions must be in English. Appropriate use of the English language is a requirement for review and publication in Forensic Genomics. For authors whose native language is not English, we recommend using a service that will aid in the translation and rewriting of material into correct and proper English usage. The Publisher offers this service for a fee prior to official submission. For more information, please contact: Editing@liebertpub.com Please note that employing the use of the Publisher's service is not required and using it, or any other language editing service, does not guarantee acceptance of any paper. All submissions are subject to peer review.

AUTHOR DISCLOSURE STATEMENTS
•    Competing Interests. A competing interest exists when an individual (or the individual's institution) has financial or personal relationships that may inappropriately influence his actions. These competing interests may be potential or actual, financial or other.
•    Personal Financial Interests. Stocks or shares in a company that may gain or lose financially from publication of the article; consulting fees or other remuneration from an organization that may gain or lose financially from publication of the article; patents or patent applications that are owned by or licensed to companies/institutions that may gain or lose value from publication of the article.
•    Funding. Research support by organizations that may gain or lose financially from publication of the article. This support includes salary, equipment, supplies, honoraria, reimbursement or prepayment for attending symposia, and other expenses.
•    Employment. Recent (within the past 5 years), current, or anticipated employment by an organization that may gain or lose financially from publication of the article.
•    Other Competing Interests. Any personal relationship which may inappropriately affect the integrity of the research reported (by an author) or the objectivity of the review of the manuscript (by a reviewer or Editor), for example, competition between investigators, previous disagreements between investigators, or bias in professional judgment.

FUNDING INFORMATION
Manuscripts should be submitted with all appropriate funding agency information, including all grant numbers, in order for proper appropriation and deposition to official databases (i.e., PubMed Central [PMC]), and indexing services.

If an article is published without this information and a post-publication correction is requested, authors will be required to provide original documentation from the funding agency specific to the study in order for an official correction statement to be considered by the Editor of Forensic Genomics.

SELF-CITATION AND SELF-PLAGIARISM  
Forensic Genomics is committed to maintaining the integrity of the peer review process by upholding the highest standards for all published articles. Any manuscript to be considered for publication will be processed through plagiarism detection software prior to peer review. Plagiarized manuscripts will be rejected immediately. While a manuscript submission may contain some redundancy in language and content (i.e., Materials and Methods) compared to work previously published by authors, self-plagiarism can infringe upon copyright. To avoid plagiarism, be sure to properly cite and reference all published works.

AFFILIATIONS
Authors should identify as their institution(s) the facility where the work was performed and executed.  Changes in an author’s affiliation after the work was completed but prior to the submission or publication of the manuscript should be noted by including an asterisk as a superscript to the name in the author listing, as well as a corresponding footnote on the title page indicating “Current Address” listing the new affiliation.   Corrections to affiliations, email addresses, or contact information due to relocation after publication is not permitted.

For further information, consult the World Medical Association’s website.  

INTERNAL REVIEW BOARD APPROVALS/WAIVERS
(as described and defined on the World Medical Association's website)

When reporting research involving human data, authors should indicate whether the procedures followed have been assessed by the responsible review committee (institutional and national), or if no formal ethics committee is available, were in accordance with the Declaration of Helsinki as revised in 2013. If doubt exists whether the research was conducted in accordance with the Helsinki Declaration, the authors must explain the rationale for their approach and demonstrate that the institutional review body explicitly approved the doubtful aspects of the study. Approval by a responsible review committee does not preclude editors from forming their own judgment whether the conduct of the research was appropriate.
If the study is judged exempt from review, a statement from the committee is be required. Informed consent by participants should always be secured. If not possible, an institutional review board must decide if this is ethically acceptable. This information should be outlined in the cover letter accompanying the submission, and in a sentence declaring adherence should be included at the beginning of the Materials and Methods section of the manuscript.

Human Subjects:  Patient Consent/Release
If applicable, it is incumbent upon the author(s) to obtain patient release statements of permission to reproduce any identifiable images and/or information of patients.

Any identifying information should not be published in descriptions or photographs unless the information is essential for scientific purposes and the patient (or parent/guardian) gives written informed consent for publication. Informed consent for this purpose requires that an identifiable patient be shown the manuscript to be submitted. Authors should disclose to these patients whether any potential identifiable material might be available via the Internet as well as in print after publication.  Nonessential identifying details should be omitted. Informed consent should be obtained if there is any doubt that anonymity can be maintained. For example, masking the eye region in photographs of patients is inadequate protection of anonymity. If identifying characteristics are de-identified, the manuscript should contain assurances/statements that such changes do not distort scientific meaning.

In keeping with patients' rights of privacy, the Journal does not require the submission of patient consent forms, but instead requires the author(s) to retain and archive all patient consent documentation. Upon submission of a manuscript for review, the authors must make a statement in a cover letter to the Editor/Journal which attests they have received and archived written patient consent.  A statement of patient consent must be included in the Methods section of the manuscript.

Ethical Treatment of Animals
All peer-reviewed submissions containing animal experiments must comply with local and national regulatory principles and contain a statement in the Materials and Methods section stating whether their national and institutional guidelines for the care and use of laboratory animals were followed.

Author Contribution Statement(s)
Authors are required to include a statement of responsibility in the manuscript after the Acknowledgments section that specifies the contribution of each author listed on the submission. If a paper is accepted for publication, these statements are published as part of the article.  Click here for the definition of Authorship.
Author Disclosure Statements

•    Competing Interests. A competing interest exists when an individual (or the individual's institution) has financial or personal relationships that may inappropriately influence his actions. These competing interests may be potential or actual, financial or other.
•    Personal Financial Interests. Stocks or shares in a company that may gain or lose financially from publication of the article; consulting fees or other remuneration from an organization that may gain or lose financially from publication of the article; patents or patent applications that are owned by or licensed to companies/institutions that may gain or lose value from publication of the article.
•    Funding. Research support by organizations that may gain or lose financially from publication of the article. This support includes salary, equipment, supplies, honoraria, reimbursement or prepayment for attending symposia, and other expenses.
•    Employment. Recent (within the past 5 years), current, or anticipated employment by an organization that may gain or lose financially from publication of the article.
•    Other Competing Interests. Any personal relationship which may inappropriately affect the integrity of the research reported (by an author) or the objectivity of the review of the manuscript (by a reviewer or Editor), for example, competition between investigators, previous disagreements between investigators, or bias in professional judgment.

COPYRIGHT AGREEMENT FORM
Upon acceptance of any manuscript, all authors will receive an email with detailed instructions and a unique, author-specific link to access and complete our online Copyright Agreement form. It is critical to ensure the accuracy of ALL authors' email addresses when uploading submissions to Manuscript Central to ensure the proper delivery of all email communications. FAILURE BY ALL AUTHORS TO SUBMIT THIS FORM WILL RESULT IN A DELAY OF PUBLICATION. The corresponding author is responsible for communicating with coauthors to ensure they have completed the online copyright form. Authors not permitted to release copyright must still return the form acknowledging the statement of the reason for not releasing the copyright. Copyright forms may also be completed by logging in to the system using an author's credentials. After logging on, click on Author Center and complete the forms located under "Manuscripts I Have Coauthored."

Published manuscripts become the sole property of the Journal and will be copyrighted by Mary Ann Liebert, Inc., unless alternate arrangements are made prior to publication, including CC-BY licensing (see below). By submitting a manuscript to the Journal, the author(s) agree(s) to each of the above conditions. In addition, the author(s) explicitly assign(s) any copyrighted ownership he/she (they) may have in such manuscript to the Journal.

OPEN ACCESS / CC-BY LICENSING
AIDS Research and Human Retroviruses is a subscription-based peer-reviewed journal with Open Access options. Creative Commons CC-BY and CC-BY-NC licensing is available for all articles published open access for a standard Article Processing Charge (APC). Please contact our Open Access Manager to order open access for your article. Learn more about open access publishing on our website.

 

RESEARCH FUNDER COMPLIANCE (FundRef)
Upon submission of a manuscript, the submitting agent will have an opportunity to enter funding/grant information. If funding information is entered correctly, the publisher will deposit the funding acknowledgements from the article as part of the standard metadata to FundRef. The entered information should include funder names, funder IDs (if available), and associated grant numbers.  Special care should be taken when entering this information to ensure total accuracy. (See CrossRef's Funder Registry for a listing of more than 13,000 international funding agencies.)
GOVERNMENT FUNDED RESEARCH
Forensic Genomics is fully NIH-, HHMI-, RCUK, and Wellcome Trust-compliant.
OPEN ACCESS
Our open access publishing solutions allow you to comply with the open access policies of your institution, government, and funding body. If you are employed or funded by the National Institute of Health (NIH), Howard Hughes Medical Institute (HHMI) the Wellcome Trust, or Research Councils UK (RCUK), please note below:
•    NIH and HHMI Public Access Policy: In order to assist our authors who have NIH funding to comply with this policy, Mary Ann Liebert, Inc. publishers will deposit the final paginated version of the published article to PubMed Central (PMC) on behalf of the authors after a 12-month embargo period. Authors need not take any action. This service is provided free of charge. Authors who wish to remove the 12-month embargo period are encouraged to consider publishing with Open Option.
•    Wellcome Trust Policy: To easily comply, you can choose to have your article published open access under the Creative Commons Attribution (CC BY) license. The publication charge will be covered by the Wellcome Trust.
•    Research Councils UK (RCUK):  To easily comply, you can choose to have your article published Open Access under the Creative Commons Attribution (CC BY) license. The publication charge will be covered by the RCUK.

FUNDING INFORMATION
Manuscripts must contain a formal Funding Information Statement which includes all appropriate funding agency information and grant numbers, in order for proper appropriation and deposition to official databases (i.e., PubMed Central [PMC]), and indexing services.  A statement should be inlcuded even if no funding was received.
If an article is published without this information and a post-publication correction is requested, authors will be required to provide original documentation from the funding agency specific to the study in order for an official correction statement to be considered by the Editor of Forensic Genomics.

DATA SHARING

Forensic Genomics strongly advocates the sharing and archiving of the data and any other artifacts that define and support the results stated in a manuscript in a suitable public repository (in accordance with valid privacy, legal, and ethical guidelines). A data availability statement should be included in the manuscript (in the Methods section or as a separate section at the end of the manuscript), describing the location of the data, with details on how it can be accessed as well as any licensing information. If the data is not publicly available or accessible, that information should also be provided.

Datasets should be cited in the reference list by Author (Year). Title. Publisher. Identifier/DOI.

Important: Please check with your funding agencies to ensure that are you following their data sharing polices. If your funding agency has additional requirements exceeding our policy, you must follow the requirements of your funder.

PREPRINT SERVERS

A preprint is a complete draft of a research paper that is shared on a public preprint server prior to submission to a journal for peer review.
 
Mary Ann Liebert, Inc., allows for papers that were previously deposited on preprint servers to be submitted to our journals, with the proviso that the author updates any preprint versions with a link to the final published article.  All submissions are subject to peer review and allowing the submission of preprint manuscripts does not guarantee publication in any Mary Ann Liebert, Inc., journal.
 
The submitting author of a paper that was previously deposited to a preprint server should include a disclosure on the title page of the manuscript indicating the name and website of the server and include the DOI number of the preprint.
 
Referencing/citing non-peer-reviewed material that is found on any preprint server is generally discouraged by Mary Ann Liebert, Inc., journals, but if it is necessary, the citation must make it clear that the content is not officially published in a journal, and can only be found on a preprint server.

Forensic Genomics recognizes the growing popularity of community non-peer-reviewed preprint repositories such as bioRxiv, arXiv, ChemRxiv, PeerJ Preprints, etc. Deposition of a preprint on a preprint server is not considered as prior publication and will not impact consideration of any manuscript submitted to Forensic Genomics. However, the existence of a publicly available preprint should be declared upon submission.

ATTENTION:  
To ensure the receipt of all communications from the journal editorial office and publisher, please whitelist the following domains to prevent spam filter detection or non-deliverables:

•    manuscriptcentral.com
•    amazonses.com
•    liebertpub.com

Failure to whitelist these domains may significantly hinder the progress of peer review on submitted manuscripts, and the production process of accepted papers.

POST-ACCEPTANCE / PRODUCTION
All accepted manuscripts will go through copyediting, typesetting, figure sizing and placement, author proofing, corrections, revisions (from corrected proofs), online-ahead-of-print release, and lastly, issue assignment. Depending on the length and complexity of any accepted submission, these steps typically take 3-6 weeks from acceptance.  Changes or alterations to a submission are not permitted after acceptance but should be addressed in page proofs.
PAGE PROOFS
Page proofs will be sent to the corresponding author as designated in Manuscript Central when the manuscript was submitted. It is the corresponding author's responsibility to share the page proofs with co-authors, if desired, and to coordinate all authors' corrections into one proof. The Publisher will not accept corrections from multiple authors/sources.
AUTHOR RESPONSE TO GALLEY PROOF
•    The corresponding author is responsible for returning corrected galley proofs generally within 72 hours of receipt.
•    If the corresponding author does not respond within that timeframe, the manuscript may be delayed in the publication schedule, or published as is, at the discretion of the Editor and Publisher.
•    If the corresponding author expects to be unavailable during the time the manuscript is in production, the Publisher should be provided with an alternate contact.  
•    Only corrections directly related to errors in typesetting and/or layout will be allowed.
•    Any requested changes related to content, or that alter the outcome of a study, will require the approval of the Editor, and may require further peer review.

POST-PUBLICATION CORRECTIONS
In the event an error is discovered after publication of an article, the corresponding author should submit the correction in writing to the editorial office for consideration.  After editor approval, alterations will be made to the online version of the article, and if the errors are significant, an official correction statement will be issued.
•    Changes to author affiliations or contact details due to relocation after publication are not permitted.
•    Corrections to meeting abstracts will be made only to the online version.  The Journal does not issue formal correction statements for corrections to meeting abstracts, regardless of the nature of the correction.
•    Correction Statements/Errata to published articles due to author error that require the reproduction of color figure(s) and/or table(s) may incur additional costs to the author(s).
CORRECTIONS TO FUNDING INFORMATION
Manuscripts should be submitted with all appropriate funding agency information, including all grant numbers, in order for proper appropriation and deposition to official databases (i.e., PubMed Central [PMC]), and indexing services.
If an article is published without this information and a post-publication correction is requested, authors will be required to provide original documentation from the funding agency specific to the study in order for an official correction statement to be considered by the Editor of Forensic Genomics.
RETRACTIONS**
Forensic Genomics and its publisher are committed to upholding the proper protocols and established standards of peer review.  Published papers found to be in violation of any of the misconduct noted in our policies, or in the accepted principles of peer review and scientific publishing, will be officially retracted from the literature.  An official retraction notice will be published, explaining in full detail the circumstances surrounding the need for a retraction.
**Any publication fees for retracted and/or withdrawn articles are nonrefundable in any circumstance.

REPRINTS
Reprints may be ordered by following the special instructions that will accompany the proofs and should be ordered at the time the corresponding author returns the corrected page proofs to the Publisher as reprints ordered after the issue is printed will be charged at a substantially higher rate.
PERMISSIONS
When reproducing copyrighted material such as figures, tables, or excerpted text, the author(s) of the submitted paper must obtain permission from the original publisher and submit it concurrently with the manuscript. The publication from which the figure or table is taken must be listed in the reference list. Finally, a footnote to a reprinted table or the legend of a reprinted figure should read, "Reprinted by permission from Jones et al." and list the appropriate reference. All permissions must be supplied at the time of submission.  Authors are responsible for any fees that may be incurred by securing permission to reproduce or adapt material from other published sources.
REUSE OF MATERIAL POSTED ON SOCIAL MEDIA
As material posted on social media platforms is usually not peer-reviewed content, it is generally not permitted as an official citation and/or reference.

SELF-CITATION AND SELF-PLAGIARISM
Forensic Genomics is committed to maintaining the integrity of the peer review process by upholding the highest standards for all published articles. Any manuscript to be considered for publication will be processed through plagiarism detection software prior to peer review. Plagiarized manuscripts will be rejected immediately. While a manuscript submission may contain some redundancy in language and content (i.e., Materials and Methods) compared to work previously published by authors, self-plagiarism can infringe upon copyright. To avoid plagiarism, be sure to properly cite and reference all published works.

DEFINITIONS OF SCIENTIFIC MISCONDUCT
Forensic Genomics follows the guidelines and rules regarding scientific misconduct put forth by the Committee on Publication Ethics (COPE), the International Committee of Medical Journal Editors (ICMJE), and the Office of Research Integrity (ORI).

Scientific misconduct and violation of publishing ethics vary and can be intentionally or unintentionally perpetrated. Some examples of misconduct and violations include, but are not limited to, the following:

•    Scientific Misconduct: Fabrication, falsification, concealment, deceptive reporting, or misrepresentation of any data constitutes misconduct and/or fraud.
•    Authorship Disputes: Deliberate misrepresentation of a scientist's contribution to the published work, or purposefully omitting the contributions of a scientist.
•    Misappropriation of the ideas of others: Improper use of scholarly exchange and activity may constitute fraud. Wholesale appropriation of such material constitutes misconduct.
•    Violation of generally accepted research practices: Serious deviation from accepted practices in proposing or carrying out research, improper manipulation of experiments to obtain biased results, deceptive statistical or analytical manipulations, or improper reporting of results constitutes misconduct and/or fraud.
•    Material failure to comply with legislative and regulatory requirements affecting research: Including but not limited to serious or substantial, repeated, willful violations of applicable local regulations and law involving the use of funds, care of animals, human subjects, investigational drugs, recombinant products, new devices, or radioactive, biologic, or chemical materials constitutes misconduct.
•    Conflict of Interest: Nondisclosure of any conflicts, direct or indirect, to the Journal which prevents you from being unbiased constitutes misconduct.
•    Deliberate misrepresentation: of qualifications, experience, or research accomplishments to advance the research program, to obtain external funding, or for other professional advancement constitutes misconduct and/or fraud.
•    Plagiarism: Purposely claiming another's work or idea as your own constitutes misconduct and/or fraud.
•    Simultaneous submission: Submitting a paper to more than one publication at the same time constitutes misconduct.

 

JOURNAL'S RESPONSE TO ALLEGATIONS OF SCIENTIFIC MISCONDUCT
Forensic Genomics and its publisher is committed to helping protect the integrity of the public scientific record by sharing reasonable concerns with authorities who are in the position to conduct an appropriate investigation into an allegation. As such, all allegations of misconduct will be referred to the Editor-In-Chief of Forensic Genomics who, in turn, will review the circumstances, possibly in consultation with associate editors and/or members of the editorial board. Initial fact-finding will usually include a request to all the involved parties to state their case and explain the circumstances, in writing. In questions of research misconduct centering on methods or technical issues, the Editor-In-Chief may confidentially consult experts who are blinded to the identity of the individuals. (If the allegation is against an editor, an outside expert will conduct the process.) If necessary, the Editor-in-Chief will elevate the situation to the author(s') instituional authorities and request further investigation(s), and will await the findings of the inquiry before rendering an actionable decision.
If an inquiry concludes there is a reasonable possibility of misconduct, the Editor-in-Chief will officially retract the paper from the Journal and the scientific record, and will publish a full explanation for the necessity of the retraction. If the paper is still under peer review, the Editor-in-Chief will withdraw the paper from consideration to the Journal.  Any author proved to commit scientific misconduct and/or fraud will be barred from sumbitting papers to Forensic Genomics.

When allegations of potential impropriety arise, the peer review and publication process for the manuscript in question will cease while the process described herein is researched. The investigation will be taken to completion even if the authors withdraw their paper during the process. In the case of allegations against reviewers or editors, they will be replaced in the review process while the matter is investigated.  Editors or reviewers who are found to have engaged in scientific misconduct will be removed from further association with Forensic Genomics and reported to their institution.
All allegations of misconduct will be kept confidential.

 

RETRACTIONS
The journal and its publisher are committed to upholding the proper protocols and established standards of peer review.  Published papers found to be in violation of any of the misconduct noted above, or in the accepted principles of peer review and scientific publishing, will be officially retracted from the literature.  No refunds will be issued for and fees paid in connection with an article that requires a formal post-publication withdrawal or retraction.

Mary Ann Liebert, Inc., publishers permits the use of accepted pre-published manuscripts for the sole purpose of pitching to news organizations under strict embargo, and with the approval of and expressed collaboration with the publisher. A watermarked PDF version of the article (not a Word document or any other editable version) may be shared only with named, personal contacts at trusted news sources upon request. News sources must be informed upon delivery of the PDF that the manuscript is for reference-only purposes and can be used only in preparation of their news coverage of the article. It is strictly prohibited to publicly share, post, or otherwise distribute the PDF in any media format. Upon official publication of the article, news organizations must link directly to the published article on the Publisher’s journal website. To coordinate publication timing and press efforts, please CLICK HERE to contact our Director of Marketing


•    Correction Statements/Errata to published articles due to author(s') error that require the reproduction of color figure(s) and/or table(s) may incur additional costs to the author(s).
•    No refunds will be issued for an article that requires a formal post-publication withdrawal or retraction.

The Office of Foreign Assets Control (OFAC) of the US Department of the Treasury administers and enforces economic and trade sanctions based on US foreign policy and national security goals against targeted foreign countries and regimes, terrorists, international narcotics traffickers, those engaged in activities related to the proliferation of weapons of mass destruction, and other threats to the national security, foreign policy or economy of the United States. OFAC acts under Presidential national emergency powers, as well as authority granted by specific legislation, to impose controls on transactions and freeze assets under US jurisdiction. Many of the sanctions are based on United Nations and other international mandates, are multilateral in scope, and involve close cooperation with allied governments. (Source: https://www.treasury.gov/about/organizational- structure/offices/pages/office-of-foreign-assets-control.aspx)

U.S.-owned scientific and medical journals would be in violation of OFAC regulations if they consider the publication of any scientific manuscripts from authors employed by the governments of any US- sanctioned country. This includes research departments of nuclear facilities as well as the various oil and gas companies which are deemed to be entities of the Government of these countries. The sanctions do not apply to submitted manuscripts from academic and/or research institutions and manuscripts originating from non-governmental clinical settings, such as hospitals and/or clinical practices. Mary Ann Liebert, Inc., publishers complies with these OFAC regulations.

Papers from US-sanctioned countries that are submitted to any Mary Ann Liebert, Inc., publishers journal must contain a confirmation statement after the conclusion section of the manuscript which indicates that each listed author is submitting the paper in their own personal professional capacity, and are not employees of any US-sanctioned government.

No financial transactions may take place between Mary Ann Liebert, Inc., publishers and any individual or organization from US-sanctioned countries.

Sanctioned Countries:

The Balkans
Belarus
Burma
Cote D’Ivoire (Ivory Coast)
Cuba
Democratic Republic of Congo
Iran
Iraq
Liberia
North Korea
Sudan
Syria
Zimbabwe

Forensic Genomics is published by Mary Ann Liebert, Inc., publishers, 140 Huguenot Street, 3rd Floor, New Rochelle, NY 10801;  Tel:  914-740-2100; Email:  Info@liebertpub.com;  Website:  www.liebertpub.com/forensic

 

The views, opinions, findings, conclusions and recommendations set forth in any Journal article are solely those of the authors of those articles and do not necessarily reflect the views, policy or position of the Journal, its Publisher, its editorial staff or any affiliated Societies and should not be attributed to any of them.